Phase 1 Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have given written consent to participate before any study activities begin.
- People of any gender.
- People aged 60 years or older at the time of signing the consent form.
- People who have a confirmed diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a condition where a specific protein builds up in the heart, either due to an inherited gene change or occurring without a known genetic cause.
- People whose diagnosis is supported by evidence of amyloid protein in the heart, shown through one of the following: a heart tissue biopsy confirming the protein buildup; OR a specific nuclear heart scan showing significant protein deposits, combined with a tissue biopsy from another part of the body confirming the same protein; OR a specific nuclear heart scan showing significant protein deposits, combined with normal blood and urine test results that rule out a different type of protein buildup.
- People whose heart ultrasound (echocardiogram) shows thickened heart walls — at least 13mm for women or at least 14mm for men (a scan taken within the past 2 years may be accepted).
- People who have experienced ongoing heart failure, shown by either at least one hospital admission for heart failure between 3 months and 2 years ago, OR a history of heart failure symptoms such as fluid buildup, shortness of breath, or leg swelling that requires ongoing treatment with a specific type of fluid-reducing medication called a loop diuretic.
Who may not be able to join:
- People with a known or suspected allergic reaction to the study treatment or related substances.
- People who have previously signed a consent form for this same study.
- People who are female and are currently pregnant, breastfeeding, planning to become pregnant, or who are capable of becoming pregnant.
- People who are currently enrolled in another interventional clinical trial (meaning they have already signed a consent form for another study involving a treatment or procedure).
- People who have taken part in research studies involving radiation exposure within the year before screening for this trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Transparency dept. 2834, Novo Nordisk A/S
Phone: (+1) 866-867-7178
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Mean Standard Uptake Value Ratio (SUVRmean) in myocardium; Net uptake rate constant (Ki) in myocardium; Change in SUVRmean in myocardium
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.